logo

For the Inventor, By the Inventor

San Antonio, TX, United States of America

Phoenix Biotechnology, Inc.


USPTO Granted Patents = 29

% Expired Patents = 58.6



Trademarks = 1

Forward Citations = 268

Loading Chart...
Loading Chart...

10 inventors (with patents filed for the assignee):

goldMedal Otis Crandell Addington (28 out of 28 patents)

silverMedal Robert A Newman (26 out of 40 patents)

bronzeMedal Peiying Yang (4 out of 8 patents)

4.  Donald C Lo (3 out of 5 patents)

5.  Linda S Kaltenbach (3 out of 3 patents)

6.  Richard J Obiso (2 out of 3 patents)

7.  Feng Zhang (1 out of 42 patents)

8.  Jose R Matos (1 out of 21 patents)

9.  Crandell Addington (1 out of 1 patent)

10.  John Joseph Koleng, Jr (1 out of 27 patents)

11.  O Crandell Addington (0 patent)


Core Competencies:
Oleandrin
Cardiac Glycoside
Viral Infection
Neurological Conditions
Triterpene
Coronavirus
Equine Encephalitis
Therapeutic Response
SCF Extract
Composition
Method of Production

29 patents:

1. 12097234 - Extract containing oleandrin and method of production thereof (2024-09-24),
2. 11806359 - Method and compositions for treating Coronavirus infection (2023-11-07),
3. 11331291 - Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders (2022-05-17),
4. 11324789 - Method and compositions for treating equine encephalitis (2022-05-10),
5. 11123387 - Method and compositions for treating viral infection (2021-09-21),
6. 11013776 - Method and compositions for treating viral infection (2021-05-25),
7. 11007239 - Method and compositions for treating viral infection (2021-05-18),
8. 10980852 - Method and compositions for treating viral infection (2021-04-20),
9. 10973785 - Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders (2021-04-13),
10. 10960037 - Method of treating neurological conditions with extract ofspecies orspecies (2021-03-30),
11. 10874704 - Method and compositions for treating viral infection (2020-12-29),
12. 10729735 - Method and compostitions for treating coronavirus infection (2020-08-04),
13. 10722482 - Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders (2020-07-28),
14. 10702567 - Method and compositions for treating viral infection (2020-07-07),
15. 10596186 - Method and compositions for treating viral infections (2020-03-24),
Company Overview
Phoenix Biotechnology, Inc. is a biopharmaceutical company based in San Antonio, Texas, specializing in the development of innovative therapies for cancer and other serious diseases. The organization focuses on leveraging advanced biotechnology to create novel treatments that aim to improve patient outcomes. With a commitment to research and development, Phoenix Biotechnology is dedicated to exploring new avenues in drug discovery and therapeutic applications, contributing to the evolving landscape of medical science.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

29 Patents

#21 in San Antonio, TX

#642 in Texas

#11,625 in US

#22,552 in the World

San Antonio, TX (US)
San Antonio, TX, United States of America

Phoenix Biotechnology, Inc.

Forward Citations = 268

10 inventors:

goldMedal Otis Crandell Addington (28 out of 28 patents)

silverMedal Robert A Newman (26 out of 40 patents)

bronzeMedal Peiying Yang (4 out of 8 patents)

4.  Donald C Lo (3 out of 5 patents)

5.  Linda S Kaltenbach (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Phoenix Biotechnology, Inc.. Retrieved from https://idiyas.com/company/phoenix-biotechnology

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…